
Advances in **CANCER RESEARCH**

Volume 78

Edited by

George F. Vande Woude

*ABL-Basic Research Program
National Cancer Institute
Frederick Cancer Research and Development Center
Frederick, Maryland*

George Klein

*Microbiology and Tumor Biology Center
Karolinska Institutet
Stockholm, Sweden*



ACADEMIC PRESS

San Diego London Boston
New York Sydney Tokyo Toronto

Contributors to Volume 78 vii

Cell Transformation by the E7 Oncoprotein of Human Papillomavirus Type 16: Interactions with Nuclear and Cytoplasmic Target Proteins

Werner Zwerschke and Pidder Jansen-Dürr

- I. Background: The Role of Papillomaviruses in Human Cancer 2
- II. Cellular E7-Binding Proteins 6
- III. Modulation of Cellular Functions by E7 9
- IV. The Role of HPV-16 E7 in Cell Proliferation and Immortalization 17
- References 22

Tumor Invasion: Role of Growth Factor-Induced Cell Motility

Alan Wells

- I. Introduction 32
- II. Tumor Invasiveness 34
- III. Cell Motility 40
- IV. Motility in Tumor Invasion 76
- V. Therapeutic Interventions 83
- VI. Summary and Future Directions 89
- References 90

Nonenzymatic Interactions between Proteinases and the Cell Surface: Novel Roles in Normal and Malignant Cell Physiology

Paolo Mignatti and Daniel B. Rifkin

- I. Introduction 103
- II. Extracellular Matrix-Degrading Proteinases: Classification and Structural Features 104
- III. Proteolysis-Independent Roles of Extracellular Matrix-Degrading Proteinases 124
- IV. Conclusions and Perspectives 143
- References 146

Molecular Pathogenesis of AIDS-Associated Kaposi's Sarcoma: Growth and Apoptosis

Kaoru Murakami-Mori, Shunsuke Mori, and Benjamin Bonavida

- I. Introduction 160
- II. Histopathogenesis 161
- III. Clinical Features 163
- IV. *In Vitro* and *in Vivo* Models 165
- V. Molecular Mechanisms of Kaposi's Sarcoma Cell Growth 168
- VI. Roles of Virus Infections in Kaposi's Sarcoma Development 179
- VII. Apoptosis in Kaposi's Sarcoma Cells 181
- VIII. Concluding Remarks and Therapeutic Implications 188
- References 190

Perspectives on Cancer Chemoprevention Research and Drug Development

Gary J. Kelloff

- I. Introduction 200
- II. Nature of Carcinogenesis 202
- III. Definition of Chemoprevention and Chemoprevention Agent Discovery 214
- IV. Chemopreventive Agent Development 272
- V. Cancer Chemoprevention at Major Cancer Target Sites 286
- VI. Surrogate End Points in Defining Chemopreventive Efficacy—Importance of Evaluating Both Phenotypic and Genotypic Effects 312
- VII. Major Issues and Challenges for Cancer Chemoprevention 314
- References 321

Index 335